8031. Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial.
作者: James F Casella.;Bruce A Barton.;Julie Kanter.;L Vandy Black.;Suvankar Majumdar.;Adlette Inati.;Yasser Wali.;Richard A Drachtman.;Miguel R Abboud.;Yurdanur Kilinc.;Beng R Fuh.;Murtadha K Al-Khabori.;Clifford M Takemoto.;Emad Salman.;Sharada A Sarnaik.;Nirmish Shah.;Claudia R Morris.;Jennifer Keates-Baleeiro.;Ashok Raj.;Ofelia A Alvarez.;Lewis L Hsu.;Alexis A Thompson.;India Y Sisler.;Betty S Pace.;Suzie A Noronha.;Joseph L Lasky.;Elena Cela de Julian.;Kamar Godder.;Courtney Dawn Thornburg.;Natalie L Kamberos.;Rachelle Nuss.;Anne M Marsh.;William C Owen.;Anne Schaefer.;Cameron K Tebbi.;Christophe F Chantrain.;Debra E Cohen.;Zeynep Karakas.;Connie M Piccone.;Alex George.;Jason M Fixler.;Tammuella C Singleton.;Thomas Moulton.;Charles T Quinn.;Clarisse Lopes de Castro Lobo.;Abdulkareem M Almomen.;Meenakshi Goyal-Khemka.;Philip Maes.;Marty Emanuele.;Rebecca T Gorney.;Claire S Padgett.;Ed Parsley.;Shari S Kronsberg.;Gregory J Kato.;Mark T Gladwin.
来源: JAMA. 2021年325卷15期1513-1523页
Although effective agents are available to prevent painful vaso-occlusive episodes of sickle cell disease (SCD), there are no disease-modifying therapies for ongoing painful vaso-occlusive episodes; treatment remains supportive. A previous phase 3 trial of poloxamer 188 reported shortened duration of painful vaso-occlusive episodes in SCD, particularly in children and participants treated with hydroxyurea.
8034. Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.
作者: Hassan Kamran.;Hani Jneid.;Waleed T Kayani.;Salim S Virani.;Glenn N Levine.;Vijay Nambi.;Umair Khalid.
来源: JAMA. 2021年325卷15期1545-1555页
Acute coronary syndrome (ACS) is a major cause of morbidity and mortality in the United States with an annual incidence of approximately 1 million. Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) reduces cardiovascular event rates after ACS.
|